MorningSignal
Research Platform
2026-09-28 13:40
type: earnings-brief date: 2026-07-27 session: PM status: provisional tags: [earnings, sellside, evening] daily_note: "[[Daily/2026-07-27]]" source_context: /Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-27_PM.json
[[Daily/2026-07-27|Daily note]] · Deterministic PM context captured 2026-07-27 20:03:40 EDT · Public-source cutoff 2026-07-27 20:00 EDT
The actionable signal is more selective than the long list of earnings beats. The strongest completed post-call evidence came from the morning cohort: AstraZeneca’s operating engine was confirmed, but unchanged guidance and a closing price near weighted value keep it a HOLD; Bank of Hawaii’s NIM repair was confirmed, yet public-deposit runoff and the 2x-plus tangible-book valuation preserve the WAIT ≤$76 entry; Alliance Resource Partners’ distribution coverage and second-half volume cadence improved enough to confirm HOLD; Coca-Cola FEMSA moved from deferred to HOLD/WAIT after a good margin print and a 6.1% stock reaction. Vodafone’s release supports the AM HOLD, but its full Q&A transcript was not publicly available, so it remains provisional.
The highest-quality AMC operating beats were Cadence and Celestica, but neither offers a clean chase. Cadence raised its full-year revenue and EPS framework as core EDA, IP, and system design all grew at double-digit rates; at $338.61, however, the shares already capitalize roughly 42x the new EPS midpoint. Celestica’s 62% revenue growth, 84% CCS growth, and materially higher 2026/2027 outlook are exceptional, but working-capital intensity rose and the stock closed at $318.24 before tomorrow’s call. AMKR is the clearest negative stock delta: Q2 revenue, margin, and EPS exceeded the prior guide, but the market punished a merely incremental Q3 sales step and the scale of the new capacity program. Do not buy that 6.5% decline until management reconciles utilization, advanced-packaging demand, and returns on $2.5B–$3.0B of 2026 capex.
The portfolio instruction is therefore patience, not broad de-risking. HOLD AZN, VOD, ARLP, CDNS, CLS, WELL, NUE, and FFIV; WAIT ≤$76 on BOH; HOLD/WAIT ≤$100 on KOF; WAIT on AMKR until the call proves capacity economics. No current TIF Analytical Ledger catalyst matched this slate, so no historical Ledger row was altered. The report retains a provisional overall status because several Tier 1/Tier 2 call gates remain objectively incomplete.
Closing prices from the deterministic public-market snapshot were: AZN $169.64 (+0.22%), VOD $15.80 (+4.29%), KOF $108.99 (+6.11%), BOH $80.02 (-4.70%), ARLP $25.63 (+3.72%), CDNS $338.61 (+3.79%), CLS $318.24 (+4.25%), AMKR $60.71 (-6.54%), WELL $248.34 (-1.48%), NUE $247.86 (+0.12%), and FFIV $407.96 (+4.02%). Price moves are same-day closes, not after-hours reactions.
| Ticker | Route | Tier | Evidence state | Decision | Prose min / measured | Objective gate |
|---|---|---|---|---|---|---|
| AZN | BMO catch-up | 1 | Current and prior full Q&A reviewed | HOLD | 1,200 / 1,308 | FINAL — POST CALL |
| VOD | BMO catch-up | 1 | Release/presentation; full Q&A absent | HOLD | 700 / 702 | PROVISIONAL — CALL GATE FAILED |
| BOH | BMO catch-up | 2 | Current and prior full Q&A reviewed | WAIT ≤$76 | 650 / 668 | FINAL — POST CALL |
| ARLP | BMO catch-up | 2 | Current and prior full Q&A reviewed | HOLD | 650 / 652 | FINAL — POST CALL |
| KOF | BMO catch-up | 2 | Current and prior full Q&A reviewed | HOLD/WAIT ≤$100 | 650 / 679 | FINAL — POST CALL |
| CDNS | AMC | 1 | Issuer release; complete call not indexed by cutoff | HOLD | 700 / 724 | PROVISIONAL — RELEASE ONLY |
| CLS | AMC | 1 | Issuer release; call 2026-07-28 | HOLD | 700 / 716 | PROVISIONAL — RELEASE ONLY |
| AMKR | AMC | 1 | Issuer release; complete call not indexed by cutoff | WAIT | 700 / 734 | PROVISIONAL — RELEASE ONLY |
| WELL | AMC | 2 | Issuer release; call 2026-07-28 | HOLD | 450 / 509 | PROVISIONAL — RELEASE ONLY |
| NUE | AMC | 2 | Issuer release; call 2026-07-28 | HOLD/WAIT | 450 / 450 | PROVISIONAL — RELEASE ONLY |
| FFIV | AMC | 2 | Issuer release; complete call not indexed by cutoff | HOLD | 450 / 450 | PROVISIONAL — RELEASE ONLY |
| 25 names | AMC | 3 | Coverage ledger below | DEFERRED | Ledger format | Valid Tier 3 deferral |
| WHR | Excluded | — | Issuer rescheduled release/call | EXCLUDED | N/A | Not a 2026-07-27 reporter |
Tier 1 was assigned where enterprise value, AI/semiconductor read-through, or prior AM importance made a miss material to the investment process. Tier 2 received full analytical treatment where the call or operating bridge could change a sector view. The remainder are explicitly logged with the missing decision datum and a dated catch-up requirement. “FINAL — POST CALL” means a complete current transcript, Q&A, and prior-quarter language comparison were all available; no company was upgraded to final on a collector conference-call flag alone.
Decision: HOLD. Confidence: medium-high. Status: FINAL — POST CALL. AM judgment: CONFIRMED. The call confirms that the consolidated 6% first-half growth rate masks a healthier ex-patent-cliff engine: management quantified revenue growth of roughly 11% excluding Farxiga and Brilinta, oncology retained mid-teens momentum, rare disease remained strong, and six Phase III programs read out positively. The result also confirms the AM constraints. Farxiga’s U.S. quarterly revenue fell about 90% after generic entry, China volume-based procurement remains a drag, Wainua failed its pivotal cardiomyopathy study, and management did not convert the EPS beat into a guidance raise. With the ADR closing at $169.64 against the AM weighted value near $171, the business delta is positive, the estimate delta is modestly positive, and the stock delta is neutral.
| Item | Pre-print stack | Actual / call evidence | Judgment |
|---|---|---|---|
| Q2 core EPS | Nasdaq $2.50; two estimates | $2.63 | +5.2%; clean at core line, adjustment bridge remains large |
| Q2 revenue | Yahoo $15.417B; $15.185B–$15.700B range | $15.384B | -0.2%; essentially in line |
| FY26 revenue | Mid-to-high-single-digit CER | Reconfirmed | No raise |
| FY26 core EPS | Low-double-digit CER | Reconfirmed | No raise |
| Valuation hurdle | About 19x–20x FY27 EPS at the AM indication | Close $169.64; weighted value ~$171 | Requires sustained double-digit EPS growth |
| TIF threshold | No open Ledger catalyst | None arrived | No Ledger mutation |
The quality of the beat rests on mix and operating leverage, not a top-line surprise. First-half revenue grew 6%, while core EPS grew 11%. Oncology grew 15% at constant exchange rates, and management described six positive Phase III events across oncology and other therapy areas. Core gross margin was about 83%. The CFO reiterated that second-half gross margin should seasonally step down, but full-year margin should remain stable to slightly higher. This language reduces the risk that Q2 margin is extrapolated mechanically. The company also disclosed a favorable one-time deferred-tax adjustment; that item should not be capitalized into FY27.
The rate-of-change tension is concentrated in CVRM. Management said Farxiga revenue fell roughly 90% in the quarter after U.S. generics entered in April. That is worse than a smooth erosion model but not worse than the loss-of-exclusivity scenario the portfolio was designed to absorb. The more important evidence is that consolidated growth remained positive and ex-Farxiga/Brilinta growth was about 11%. China continues to suffer volume-based procurement and local competition. Management remained strategically bullish and emphasized learning, collaboration, and competing locally, but it did not provide a numeric China recovery bridge. That answer preserved optionality without reducing forecast risk.
Pipeline evidence was mixed rather than merely “six positive readouts.” Wainua did not meet its primary endpoint in CARDIO-TTRansform. In Q&A, management argued that cliramitug should not be read through directly because its study is an add-on to stabilizers or silencers, not a monotherapy design. That is a credible mechanistic distinction, but it is not proof of efficacy. Management also retained its $80B risk-adjusted 2030 ambition and framed more than 20 upcoming Phase III readouts as the replacement engine. The correct forecast treatment is diversified option value with a haircut for binary attrition, not a smooth pipeline annuity.
| Analyst / topic | Management answer | Grade | Investment implication |
|---|---|---|---|
| Rajan Sharma, Goldman Sachs — oral PCSK9 and Sone-Ve peak opportunity | Gave 1H27 data timing and described a $3B–$5B Sone-Ve opportunity, but withheld pricing | B | Material upside remains, but price and launch economics are not model-ready |
| Gonzalo Artiach, Danske Bank — Wainua read-through to cliramitug | Distinguished the add-on design from monotherapy and explained trial context | B | Reduces direct negative read-through; does not remove modality risk |
| Steve Scala, TD Cowen — China competition | Reaffirmed long-term conviction and local operating strategy without a quantified mitigation curve | C+ | China remains an unresolved estimate risk |
| Sarita Kapila, Morgan Stanley — AVANZAR hierarchy | Clarified that success can be demonstrated in either the intent-to-treat or biomarker population | B | Preserves regulatory optionality but increases outcome complexity |
| 2027 guidance question | Deferred detailed guidance until the budget and additional readouts are complete | C | No basis for a post-call FY27 estimate step-up |
Compared with the Q1 call, two language changes matter. First, Q1 emphasized total revenue growth of 8% and a core gross margin near 83%; Q2 slowed to 6% revenue growth while management still held the same full-year margin language. That is a modest negative rate of change in reported growth, partly explained by generic Farxiga. Second, the Q1 call treated Farxiga generic entry as an April event to be absorbed; Q2 supplied the first hard evidence of approximately 90% quarterly U.S. erosion. The risk moved from forecast to fact, but the diversified portfolio absorbed it. The main unresolved omissions are the 2027 bridge, a numeric China recovery path, and launch economics for the highest-value pipeline assets.
The AM release-only range of $7.65–$7.85 for FY26 core EPS remains appropriate. The call does not justify moving above it because guidance was unchanged and the favorable tax item is not recurring. For FY27, retain $8.60–$9.00. Upside requires oncology growth at least 12%, a stable full-year core margin, and successful launches/readouts; downside emerges if China remains down double digits and additional high-value trials fail. At $169.64, the base case already prices the middle of that range at a high-teens multiple.
| Thesis pillar | AM state | Post-call evidence | New state |
|---|---|---|---|
| Oncology/rare disease replace mature franchises | Strong | Oncology +15% CER; six positive Phase III events | Strengthened |
| Farxiga erosion is absorbable | Forecast risk | U.S. quarterly revenue about -90%; group still grows | Confirmed, but cushion consumed |
| China stabilizes | Unresolved | Strategy reiterated; no numeric bridge | Unchanged |
| Pipeline breadth offsets binary risk | Mixed | Wainua miss plus multiple wins | Mixed |
| Valuation offers asymmetry | Weak | Close near weighted value | Weak |
Old narrative: a diversified oncology and rare-disease compounder carrying patent, China, and trial risk. New narrative: the portfolio is successfully absorbing an abrupt Farxiga cliff, but the unchanged guide and unquantified 2027/China bridge make the earnings beat confirmation rather than a new acceleration regime.
The principal variant view is that consensus may overstate the durability of the reported core operating leverage while understating the breadth of replacement assets. The skeptical model capitalizes recurring intangible amortization and assumes the oncology portfolio eventually faces the same erosion now visible in CVRM. The constructive model treats those accounting charges as the cost of an already-funded platform whose independent launches can more than replace Farxiga. Today’s evidence narrows neither side completely: product growth and the ex-Farxiga revenue rate validate the platform, while the core/reported profit gap and Wainua miss validate the required discount. This is why a high-quality quarter can still produce a HOLD.
The next catalytic sequence is more important than a single quarterly print. The portfolio needs positive readouts to translate into regulatory filings, launches, and forecastable revenue. Track the highest-value readouts individually, not as an aggregate “20-plus” count; require management to disclose eligible populations, treatment setting, competitor standard of care, and launch timing before assigning full probability-adjusted value. For China, monitor sequential product volumes and price/mix rather than management’s strategic confidence. For Farxiga, compare the quarterly revenue loss with the incremental oncology and rare-disease dollars to test whether replacement remains self-funded.
Action: HOLD; do not add above roughly $171. Revisit at $155–$160 or after FY27 core EPS evidence moves sustainably above $9.00. Confirmation: CER revenue at least 7%, core EPS at least 10%, oncology at least 12%, and China contraction moderating. Falsification: a guide cut, two quarters of oncology below 10%, material China deterioration without offsets, or clustered high-value Phase III failures.
Sources: issuer H1/Q2 release, current full transcript, Q1 transcript, and the 2026-07-27 AM brief.
Decision: HOLD. Confidence: medium. Status: PROVISIONAL — CALL GATE FAILED. AM judgment: CONFIRMED on action, PARTIAL on operating interpretation. The release and presentation confirm group service-revenue growth of 5.2%, adjusted EBITDAaL growth of 6.2%, Germany’s improvement to 1.2%, Africa’s acceleration to 12.6%, and Business growth of 5.0%. They also confirm the AM warning: the new €13.0B–€13.3B FY27 EBITDAaL range principally incorporates nine months of Safaricom, while adjusted free-cash-flow guidance remains €2.6B–€2.9B. The ADR’s 4.29% gain to $15.80 prices the release near the AM base case.
The prior stack remains decisive. Vodafone’s company-collected consensus put FY27 EBITDAaL near €13.115B. The updated midpoint of €13.15B therefore clears neither a large published-estimate hurdle nor the valuation-implied requirement for a cash-flow upgrade. Operational quality is better than that mechanical guide bridge: EBITDAaL grew about 100 basis points faster than service revenue, and the like-for-like margin rose. Germany is growing again, incoming customer economics and cable NPS reportedly improved, and higher-growth African/digital operations are expanding the mix. Yet the UK slowed to 0.6% service-revenue growth from 1.2%, German customer counts remain a watch item, and the consolidation of Safaricom introduces minority-interest, currency, and leverage complexity.
The business delta is positive because the European repair and group operating leverage are visible. The estimate delta is only slightly positive because the new range is a scope change and free cash flow did not rise. The stock delta is neutral-to-negative after the move: at roughly 10x forward ADR earnings, the valuation is not excessive, but a telecom with unresolved integration and leverage questions should not be valued on adjusted EBITDA alone.
The release also leaves a wide cash-quality dispersion around the same EBITDA outcome. A favorable case combines German customer stabilization, UK synergy capture, and Safaricom growth with contained spectrum and integration cash costs. A less favorable case reaches the same consolidated EBITDA through African currency/inflation translation and cost cutting while European volumes weaken and attributable cash is diluted by minorities. Both can report similar headline growth. The complete call must therefore bridge regional EBITDA to attributable FCF and net debt before the earnings quality can be called final.
The full-session gate failed for a specific reason. Vodafone’s official results page, presentation, and spreadsheet were public, but a complete current Q&A transcript with analyst identities and management answers was not available by the cutoff. A summary or conference-call flag is not transcript proof. Consequently, analyst exchange counts, answer grades, tone shifts, and prior-quarter Q&A language deltas remain unavailable. The unanswered questions are the exact Safaricom bridge from EBITDA to attributable free cash flow, the cause of UK deceleration, the timing of German volume stabilization, and restructuring/integration cash costs.
Old narrative: a low-multiple European restructuring dependent on Germany stabilization and UK integration. New narrative: the repair is broadening through Germany, Africa, Business, and margin, but the formal guidance increase is mostly consolidation accounting and the decisive cash proof remains absent. Retain FY27 EBITDAaL at €13.1B–€13.3B and adjusted FCF at €2.75B–€2.90B; for FY28, €13.8B–€14.4B remains a scenario range, not guidance.
Attributable value is most sensitive to two variables: legacy-Europe cash conversion and the multiple assigned to faster-growing African assets after minorities. A bear value near $12.80 assumes Germany stalls, UK integration consumes cash, and adjusted FCF falls below €2.6B. A base value near $16 assumes the guide is delivered and leverage normalizes. A bull value around $19.20 requires Germany and the UK both above 2% growth plus visible Safaricom cash contribution. The current $15.80 close sits at the base case; the release does not justify moving scenario weights toward the bull until the missing call evidence arrives. Price discipline remains essential.
Action: HOLD; do not chase $15.80. Prefer an entry below $14.50 absent a true cash-flow upgrade. Confirmation: Germany above 1% and trending toward 2%, UK back above 1%, FY27 EBITDAaL at least €13.2B, adjusted FCF at least €2.8B, and leverage in the lower half of the policy range. Falsification: renewed German contraction, material UK synergy slippage, adjusted FCF below €2.6B, or leverage above policy without a credible bridge.
Sources: issuer trading update, issuer presentation, and official results page.
Decision: WAIT at or below $76. Confidence: medium-high. Status: FINAL — POST CALL. AM judgment: CONFIRMED. The call validated the core AM thesis: NIM expansion, expense control, and balance-sheet capital are improving, but the public-deposit runoff, deposit competition, and valuation make the stock price—not the earnings direction—the binding constraint. The shares reversed a positive premarket indication and closed down 4.70% at $80.02. That negative stock delta improves the asymmetry but does not yet reach the preferred entry.
Q2 EPS was $1.47, NIM was 2.78% for a ninth consecutive quarterly expansion, net interest income was $153.6M, and PPNR was $85.7M, up 34.6% year over year. Management maintained a roughly 2.9% year-end NIM objective. It expects $100M–$200M of lower average earning assets in Q3, approximately $112.5M of expenses in each of Q3 and Q4, and about 3% full-year expense growth. Total deposit cost was 1.27%. These specifics preserve the positive FY1 earnings bridge while preventing an aggressive annualization of Q2.
The main call negative was funding mix. Management disclosed about $2B of public deposits and expected 10%–15% runoff at a roughly 3.5%–4% cost. Competitive pressure has not disappeared, and Q2 average deposits declined. Credit also introduced a manageable but real watch item: criticized assets rose to 2.81% from 2.12%, largely because of one secured borrower; net charge-offs were 10 basis points and nonperforming assets were 8 basis points. The company’s longer-run normalized NIM ambition of 3.25%–3.50% remains several years away.
Kelly Motta of KBW’s Q&A sequence was the most decision-useful. Management quantified the public-deposit balance and runoff assumptions, gave the $112.5M expense run rate, and explained the earning-asset decline. Those answers merit A- for specificity. On the 2.9% year-end NIM goal, management retained the target but acknowledged that its path can incorporate a possible rate hike; grade B, because the target is clear but partly rate-dependent. On normalized NIM, management supplied a 3.25%–3.50% destination but a “couple of years” timeline; grade B-, useful for terminal economics but not a near-term catalyst.
Compared with Q1, the positive rate of change moderated. Q1 NIM expanded 13 basis points and management described a path toward 2.9%; Q2 expansion slowed to four basis points, though the target remained. Q1 deposit cost fell 17 basis points to 1.26% with a 36% beta; Q2 cost edged to 1.27% and management emphasized competition and public-deposit runoff. The old narrative of accelerating NIM repair therefore becomes a narrative of continuing but decelerating repair. The operating thesis is intact; the pace is less one-way.
Retain FY26 EPS at $6.05–$6.15 and FY27 at $6.85–$7.10. The NIM and expense evidence offset a small revenue shortfall, but the deposit and asset outlook limits upside. At $80.02, the shares remain above 2x Q2 tangible book of $38.01. The business delta is positive, the estimate delta is slightly positive, and the stock delta is now positive for prospective buyers because the price fell—but the margin of safety remains insufficient.
The valuation frame prevents a good operating result from becoming an automatic buy. At $76, the shares would trade at roughly 2.0x current tangible book and about 11x the center of FY27 EPS; that still embeds above-peer franchise quality but gives some room for a slower NIM path. A $70 bear case assumes margin slips and credit normalizes; an $82 base assumes the disclosed NIM and expense path; a $96 bull case needs NIM above 2.9%, clean credit, and FY27 EPS above $7.10. The weighted value remains near the low $80s, so the new close is fair rather than cheap.
Action: WAIT for $76 or lower. Confirmation: NIM at least 2.80% in Q3 and about 2.90% by year-end, deposit runoff inside the disclosed range, charge-offs below 20 basis points, and expenses near the stated run rate. Falsification: NIM below 2.70%, deposit costs rising faster than asset yields, criticized assets broadening beyond the named borrower, or FY27 EPS falling below $6.60.
Sources: issuer Q2 release, current full transcript, and Q1 transcript.
Decision: HOLD. Confidence: medium-high. Status: FINAL — POST CALL. AM judgment: CONFIRMED. The call strengthened the distribution and volume bridge that mattered more than the thin-consensus headline miss. Q2 revenue was $551.6M, EPU was $0.61, adjusted EBITDA was $185.7M, distribution coverage improved to 1.39x, and net leverage was 0.67x. The units closed up 3.72% at $25.63, approximately the AM weighted value, so the evidence supports owning rather than adding.
The most important operating change is cadence. The first quarter’s longwall moves and weather disruptions made timing the principal execution risk. Management now says the longwall work is complete, Hamilton production should roughly double sequentially in Q3, and both Q3 and Q4 should approach nine million tons. That is an A-quality answer to Matt Key of Texas Capital because it ties the recovery to a physical mine schedule and quantifies the volume consequence. The company also added roughly 21.2M tons of future commitments, improving contracted visibility even as market coal pricing normalizes.
Distribution protection improved. Coverage rose from about 1.0x in Q1 to 1.39x in Q2, while net leverage stayed below 1x. The stronger coverage is not merely a price outcome; volume recovery and disciplined capital allocation contribute. Management continues to evaluate small mineral/ground acquisitions and M&A, but framed them inside balance-sheet constraints. That answer deserves B+: discipline was explicit, although no hard return threshold was disclosed. The absence of a numeric acquisition hurdle is the main capital-allocation omission.
Michael Mathison of Sidoti elicited useful normalized-balance-sheet detail. Management described inventory at roughly half to three-quarters of a normal level and indicated that about $3M of quarterly equity income could be sustainable. Grade B+ because the answer helps normalize working capital and non-operating earnings, but the durability of equity income remains exposed to asset performance. On AllDale and the mineral portfolio, the call supported optionality without enough data to assign material present value.
The prior-quarter language comparison is constructive. Q1 emphasized longwall timing, weather, roughly 1.0x coverage, and price normalization. Q2 moved to completed longwalls, quantified nine-million-ton quarterly cadence, 1.39x coverage, and 21.2M tons of additional commitments. The physical bottleneck moved from active disruption to execution follow-through. The bear case remains that benchmark coal prices decline faster than contracted tons and cost relief; the bull case is that contracted volume and a low-leverage balance sheet protect the distribution through the normalization.
The cash distribution remains the practical underwriting anchor. At the current unit price, investors are being paid to wait, but only if coverage stays above 1x through weaker spot pricing and maintenance spending. Contract tonnage reduces volume and price exposure but does not eliminate counterparty, quality, transport, or reopen risk. The correct dashboard is therefore quarterly tons versus the nine-million target, realized price versus unit cost, cash coverage after maintenance capital, and net leverage—not reported EPU alone. A high yield should be treated as compensation for commodity duration, not evidence of undervaluation by itself.
Retain FY26 adjusted EBITDA in the AM scenario range rather than capitalizing a single quarter. The Q2 evidence modestly raises second-half volume confidence but not long-term coal prices. Business delta: positive. Estimate delta: modestly positive. Stock delta: neutral after the 3.72% rise to weighted value. Old narrative: a high-yield coal partnership navigating disrupted production and normalization. New narrative: the maintenance bottleneck is behind it, coverage is rebuilding, and contracted volume improves the second-half bridge, but commodity duration still caps the multiple.
Action: HOLD and collect the distribution. Add only below roughly $23 or after two consecutive quarters with coverage at least 1.25x and net leverage below 1.0x. Confirmation: Q3/Q4 volume near nine million tons, coverage at least 1.25x, and no material unit-cost surprise. Falsification: coverage below 1.0x, net leverage above 1.5x, material contract cancellations, or another operational interruption that breaks the second-half cadence.
Sources: issuer release, current full transcript, and Q1 transcript.
Decision: HOLD; WAIT at or below $100 for new money. Confidence: medium-high. Status: FINAL — POST CALL. AM judgment: the DEFERRED state was correctly resolved, not contradicted. KOF delivered a high-quality margin quarter: consolidated volume grew 3.5% to roughly 1.1B unit cases, revenue rose 4.7% reported and 6.6% currency neutral to MXN76.3B, gross profit increased 8.8%, and gross margin expanded 180 basis points to 47.1%. Adjusted EBITDA rose 12.1% to about MXN15B and margin expanded 130 basis points to 19.7%. Excluding a MXN265M insurance recovery, EBITDA still rose about 10.1% and margin expanded roughly 90 basis points. The stock’s 6.11% gain to $108.99 recognizes that quality and removes the near-term entry asymmetry.
The geographic volume bridge was better than feared. Brazil grew 5.2% and Colombia 17.7%. Mexico remained the key debate: management said the first two months of the quarter were down about 3.5%, followed by roughly 12% growth in June against an easier comparison. Ben Theurer of Berenberg obtained the clearest chronology; grade A because management separated the monthly cadence and acknowledged that the market remains challenging. The evidence supports a roughly flat full-year Mexico outcome rather than a clean structural reacceleration.
Margin quality is credible but not risk-free. Management said approximately 85% of the combined tax and inflation impact had been passed through, with the remainder expected by August. Raw-material hedges cover 2027 sugar, high-fructose corn syrup, and aluminum, while PET hedging lags. That answer was specific enough for A-: it reduces near-term input uncertainty but identifies PET as the residual exposure. The shift toward one-way multiserve packaging also complicates mix and returnable economics.
Henrique Morello of Morgan Stanley pressed on margin sustainability. Management tied gains to operating leverage in Brazil and Colombia but did not quantify a normalized margin or the portion attributable to price/cost timing; grade B-. Carlos Laboy of HSBC asked about refillables. Management described a two-liter refillable pilot and acknowledged that the current price point needs adjustment; grade B, because it exposed the commercial bottleneck rather than dismissing it. On capital return, management deferred timing to the board; grade C, an unresolved omission after strong cash generation.
Compared with Q1, Mexico improved sequentially. Q1 Mexico volume declined 2.6% while management emphasized share gains and a difficult consumer backdrop. Q2 consolidated volume grew 3.5%, Mexico’s June turned positive against easier comparisons, and gross margin expanded substantially. The narrative therefore changes from defensive share protection to geographically diversified growth with a tentative Mexico turn. That turn is not yet proven because one favorable month carries base effects.
The valuation debate is between a durable consumer franchise and a macro/currency-sensitive bottler. The franchise earns structural advantages through route density, cold-drink equipment, refillable packaging, and Coca-Cola brand access. The macro side can still overwhelm those advantages when disposable income, excise taxes, currency, PET, and sugar move together. The Q2 result shows that price/mix and procurement can defend profit without sacrificing consolidated volume, but Mexico’s uneven monthly path means elasticity has not disappeared. This supports a premium to ordinary staples distributors, not an unlimited multiple.
The business delta is strongly positive, the estimate delta is positive through margin, and the stock delta is negative for prospective buyers after the 6.11% gain. A full FY1/FY2 bridge requires the post-quarter consensus refresh, but the print supports low-double-digit EBITDA growth if Mexico stays roughly flat and input hedges hold. The bear case is volume elasticity after price increases, weak Mexico, and PET/currency pressure. The bull case is sustained Brazil/Colombia leverage, market-share gains, and a Mexican volume recovery.
Action: HOLD existing exposure; wait at or below $100 for new money. Confirmation: Mexico non-negative for the second half, consolidated volume at least low single digits, adjusted EBITDA margin near 19.5% or better, and price/cost recovery complete by August. Falsification: renewed mid-single-digit Mexico contraction, gross-margin reversal greater than 100 basis points, or material PET/currency pressure without pricing recovery.
Sources: issuer-release public mirror, current full transcript, and Q1 transcript.
Decision: HOLD; do not chase. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Cadence produced the cleanest large-cap software print in the slate: Q2 revenue was $1.584B, up 24%; non-GAAP EPS was $2.11 versus $1.65 a year earlier; non-GAAP operating margin was 45.5% versus 42.8%; backlog reached $8.1B and remaining performance obligations $4.2B. The company raised its full-year framework. The problem is price: at $338.61 and the new non-GAAP EPS midpoint of $8.10, the shares trade at roughly 41.8x current-year earnings. The operating beat strengthens the thesis, but the valuation still requires durable high-teens organic growth and continued margin execution.
The collector’s dated calendar EPS estimate was around the high-$1s/low-$2s depending on source and treatment; the issuer’s $2.11 non-GAAP result cleared the reliable published hurdle. Revenue exceeded the prior company framework and accelerated year over year. Q1’s full-year outlook was revenue of $6.125B–$6.225B, non-GAAP operating margin of 43.5%–44.5%, non-GAAP EPS of $7.85–$7.95, and operating cash flow of $1.875B–$1.975B. The new FY26 revenue range is $6.26B–$6.34B and non-GAAP EPS is $8.05–$8.15. That is a midpoint lift of roughly $125M in revenue and $0.20 in EPS. The full-year raise is economically meaningful, not just a penny beat.
The growth composition supports a broader platform thesis. Core EDA revenue grew about 18%, IP about 40%, and System Design and Analysis about 37%. Cadence added 12 new hardware customers. This matters because AI compute complexity increases verification, packaging, thermal, electromagnetic, and system-analysis workloads together. The company is monetizing the design stack rather than relying on a single simulator or license cycle. Backlog and RPO also reduce near-term revenue risk.
The quality caveat is that the full earnings bridge and cash conversion need the call. GAAP operating margin was 28.4%, materially below the 45.5% non-GAAP margin, reflecting stock compensation, amortization, and acquisition-related adjustments. At a 42x current-year multiple, investors should not treat every adjustment as costless. The release also does not by itself answer whether China/export controls, hardware supply, and acquisition integration influence the FY2 margin path.
The FY1 estimate delta is directly positive: move the working non-GAAP EPS range to $8.05–$8.15 and revenue to the company’s $6.26B–$6.34B. For FY2, do not mechanically annualize Q2’s 24% growth. A reasonable provisional framework is mid-teens revenue growth and EPS growth modestly faster through mix and scale, contingent on continued IP/System Design strength. The valuation-implied bar is at least high-teens EPS growth or sustained 40x-plus quality. A normalization to 35x $8.10 implies about $284; 40x implies $324; 45x implies $365. The close already discounts a result between the upper base and bull cases.
| Thesis pillar | Prior state | Release evidence | State |
|---|---|---|---|
| AI complexity drives design intensity | Strong | Core EDA +18%, IP +40%, System Design +37% | Strengthened |
| Platform breadth expands wallet share | Constructive | 12 new hardware customers; $8.1B backlog | Strengthened |
| Margin scales with growth | Constructive | Non-GAAP margin +270 bps | Strengthened |
| Cash/GAAP quality supports premium multiple | Unresolved | Large GAAP/non-GAAP margin gap | Unresolved |
| Valuation offers upside | Weak | ~41.8x FY26 midpoint | Weak |
Old narrative: an EDA compounder benefiting from AI-driven complexity but priced for durable execution. New narrative: growth has broadened into IP, system analysis, and hardware with a real full-year raise; the business case strengthened faster than the valuation case.
The complete public call transcript was not indexed by 20:00 EDT. Call highlights do not satisfy the transcript gate, so Q&A grades, prior-quarter language changes, and tone judgments remain pending. Required questions are: organic versus acquisition contribution to each growth engine; cash conversion and the GAAP/non-GAAP expense bridge; China/export-control sensitivity; hardware supply and backlog duration; and what FY2 growth the current capacity plan supports.
Action: HOLD; no chase at $338.61. Prefer entry below roughly $300, or add after FY27 EPS evidence supports at least $9.25 without a lower-quality adjustment bridge. Confirmation: full-year revenue at least $6.30B, non-GAAP margin at least 44%, RPO growth, and cash flow inside the prior range or better. Falsification: a material guide cut, core EDA below low-double-digit growth, backlog contraction, or a cash-conversion miss.
Source: Cadence Q2 issuer release.
Decision: HOLD; do not chase before the call. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Celestica delivered the highest growth and guidance delta in the evening slate. Revenue rose 62% to $4.70B versus guidance of $4.15B–$4.45B. Adjusted EPS was $2.54 versus a $2.14–$2.34 guide, and adjusted operating margin reached 8.2% versus a 7.4% guide. The company raised 2026 revenue to $20.5B from $19.0B, adjusted EPS to $11.30 from $10.15, adjusted operating margin to 8.4% from 8.1%, and free cash flow to $600M from $500M. It also expects 2027 revenue growth above 65% with EPS growing faster. Those are thesis-strengthening numbers; the risk is that the $318.24 close and working-capital build capitalize much of the upside before tomorrow’s call.
Connectivity and Cloud Solutions revenue was $3.81B, up 84%, with an 8.7% segment margin. Hyperscaler revenue was approximately $1.9B, up 58%. Advanced Technology Solutions revenue was $0.89B, up 8%, while its margin improved to 6.3% from 5.3%. The mix shows that AI/data-center demand is not only driving volume; it is supporting margin despite rapid scaling. Q3 guidance of $5.25B–$5.55B revenue and $2.88–$3.08 adjusted EPS implies another sequential step.
The 2026 raise is substantial. Revenue guidance increased 7.9%, adjusted EPS 11.3%, and free cash flow 20%. EPS and FCF rising faster than revenue argues for favorable mix and execution. The 2027 statement is even more aggressive: growth above 65% from a larger 2026 base would move the company into a very different scale class. That forecast needs contract, customer, and capacity evidence on the call before being capitalized fully.
Working capital is the key quality check. Inventory rose to about $3.402B from $2.188B at December, and accounts receivable increased to about $3.338B from $2.638B. Cash was $535.7M. Some build is expected when revenue scales this rapidly and customers may fund or support programs, but the balance-sheet intensity means adjusted EPS alone is insufficient. A total-return-swap gain contributed about $0.90 pre-tax to GAAP earnings, another reason to use adjusted operating performance and cash rather than headline GAAP EPS.
Adopt the new FY26 operating framework: $20.5B revenue, $11.30 adjusted EPS, 8.4% adjusted operating margin, and $600M FCF as the center case. For FY27, the company’s greater-than-65% revenue growth statement implies more than $33.8B. Treat that as a provisional management hurdle until the call identifies customer programs, content, and capacity. Even if EPS grows faster, execution risk rises nonlinearly with working capital, supply, customer concentration, and manufacturing ramp.
At $318.24, the stock is about 28.2x FY26 EPS. That multiple is not unreasonable for the stated growth, but it presumes the 2027 outlook is credible and funded. A bear case of 22x $11.30 gives $249; a base case of 28x gives $316; a bull case of 34x gives $384. The close is almost exactly base case. Business delta: strongly positive. Estimate delta: strongly positive. Stock delta: neutral after the 4.25% rise.
| Thesis pillar | Release evidence | State |
|---|---|---|
| AI infrastructure demand is durable | CCS +84%; hyperscaler revenue +58% | Strengthened |
| Scale expands margin | Adjusted margin 8.2%; FY guide 8.4% | Strengthened |
| Growth converts to cash | FCF guide raised to $600M | Strengthened, but working capital is heavy |
| Capacity/customer concentration is controlled | 2027 >65% growth asserted; details pending | Unresolved |
| Valuation has margin of safety | ~28x FY26; base value near close | Weak |
Old narrative: an outsourced manufacturing beneficiary of AI infrastructure with improving mix. New narrative: Celestica is becoming a hyperscaler-scale compute platform, but the rate of growth now makes funding, concentration, and ramp execution as important as demand.
The issuer call is scheduled for 2026-07-28, so the current transcript and Q&A do not exist at this report cutoff. Required call questions are customer concentration behind the 2027 outlook, liquid-cooling/networking versus compute mix, inventory ownership and cancellation protection, capacity capex, and the FCF bridge.
Action: HOLD; no chase above $318 before the call. Prefer entry below roughly $280 or after the call converts the 2027 statement into contracted program evidence. Confirmation: Q3 revenue above $5.25B, adjusted margin at least 8%, FCF path intact, and inventory turns stabilizing. Falsification: 2027 growth retreat below 40%, margin below 7.5%, customer cancellation, or a working-capital build that consumes the FCF raise.
Source: Celestica Q2 issuer release.
Decision: WAIT; do not buy the 6.54% decline until call economics are reconciled. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Amkor’s reported quarter was strong: revenue reached $1.898B, gross margin 16.8%, operating margin 10.5%, EPS $0.70, and EBITDA $400M. All improved sharply from both Q1 and the prior year. Yet the stock closed at $60.71, down 6.54%, because Q3 revenue guidance of $1.95B–$2.05B implies only modest sequential growth after a large Q2 step, while the company is committing $2.5B–$3.0B of 2026 capex. The market is questioning incremental returns and utilization, not the backward-looking beat.
The prior Q2 company guide was revenue of $1.75B–$1.85B, gross margin of 14.5%–15.5%, and EPS of $0.42–$0.52. Actuals exceeded the top end by $48M on revenue, 130 basis points on gross margin, and $0.18 on EPS. Advanced Products revenue was $1.557B versus $1.372B in Q1 and $1.228B a year ago. The top-ten-customer share fell to 66% from 68% in Q1 and 72% a year ago, a favorable diversification rate of change. End-market mix was communications 42%, computing 22%, automotive/industrial 22%, and consumer 14%.
Q3 guidance is $1.95B–$2.05B revenue, 18.5%–19.5% gross margin, and $0.72–$0.82 EPS. The margin and EPS guidance are better than the sales cadence: at midpoint, revenue rises about 5.4% sequentially while gross margin expands roughly 220 basis points. The implied mix shift toward advanced packaging is constructive. The concern is whether the margin step is durable or depends on temporary utilization, pricing, and product timing.
The balance sheet has roughly $2.5B of cash and $2.5B of debt, giving Amkor room to invest. But capex of $2.5B–$3.0B is larger than annualized Q2 EBITDA and will depress free cash flow. Partnerships and demand tied to leading-edge compute can justify the program only if customer commitments, utilization, and pricing protect returns. The full transcript is therefore necessary before converting an earnings beat into a buy recommendation.
The FY1 estimate delta is positive because Q2 beat and Q3 margin guidance are above the prior run rate. The FY2 range is more uncertain: depreciation, ramp costs, and financing must be bridged against advanced-packaging revenue. The business delta is positive, but the stock delta is negative because the market now demands evidence beyond the current print. The selloff is informative: expectations had moved ahead of near-term sales.
Scenario value depends more on the return profile than the current EPS beat. A bear case applies a low-teens multiple to normalized earnings if capex depresses FCF and new facilities ramp slowly. A base case assumes Q3’s margin step persists and customer-backed capacity reaches normal utilization. A bull case requires leading-edge packaging demand to keep supply tight enough for pricing and double-digit returns on invested capital. Until management quantifies those inputs, an apparently low forward P/E can be a false signal because depreciation and cash outlay arrive before revenue maturity.
| Thesis pillar | Release evidence | State |
|---|---|---|
| Advanced packaging drives mix | Advanced Products $1.557B; Q3 margin guide higher | Strengthened |
| Customer concentration declines | Top ten 66% vs 72% a year ago | Strengthened |
| Capex earns attractive returns | $2.5B–$3.0B program; commitments not quantified | Unresolved / riskier |
| Near-term demand accelerates | Q3 sales midpoint only +5% sequentially | Mixed |
| Balance sheet funds the ramp | Cash roughly equals debt | Adequate |
Old narrative: a cyclical OSAT gaining AI/advanced-packaging content. New narrative: mix and margin are improving faster than revenue, but the thesis has shifted from demand discovery to capital-efficiency proof. A strong Q2 is not enough if the new fabs and tools run below target utilization.
The 17:00 EDT call occurred, but a complete public transcript with all Q&A was not indexed by the 20:00 cutoff. Headline summaries are insufficient. Required questions are customer-backed versus speculative capex, capacity utilization by site, Q3 margin drivers, depreciation timing, and cash conversion. Prior-quarter full-call comparison also remains pending.
Action: WAIT. Do not buy the decline without the transcript. A price below roughly $52 or evidence that 18.5%–19.5% gross margin is sustainable with contracted utilization would improve asymmetry. Confirmation: Q3 revenue at least $2.0B, gross margin at least 18.5%, advanced-products growth, and quantified customer commitments. Falsification: utilization below plan, gross margin back below 16%, capex rising without revenue commitments, or negative FCF extending beyond the build phase.
Sources: Q2 Business Wire public mirror and Q1 issuer release/prior guide.
Decision: HOLD; wait below roughly $220 for new money. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Normalized FFO was $1.60 per share, up 25%, and management raised the full-year normalized-FFO range to $6.36–$6.44 from $6.21–$6.35. Senior Housing Operating same-store NOI grew 15.5%; SHO revenue increased 9.2% through approximately 330 basis points of occupancy expansion and 5.2% RevPOR growth. Net debt to adjusted EBITDA was 2.99x, liquidity was $9.5B, and the dividend increased 15% to $0.85. This is strong real-estate operating evidence, but the $248.34 close equates to roughly 38.8x the new FFO midpoint.
The operating engine is occupancy plus pricing plus scale. Management raised SHO same-store NOI guidance to 18.5%–21.5%, implying that the second-half comparison remains strong. The balance sheet gives the company acquisition and development flexibility, and the dividend increase signals confidence. The risk is valuation and duration: at nearly 39x FFO, the stock needs sustained double-digit property-level growth, accretive external deployment, and no material increase in financing cost.
The mechanism is favorable but mean-reverting. Senior-housing occupancy can continue to recover as demographic demand grows and new construction remains constrained, while RevPOR adds pricing. Yet occupancy gains naturally slow near stabilized levels, labor can absorb revenue growth, and external acquisitions become less accretive when cap rates fail to compensate for capital costs. A premium FFO multiple is warranted by this runway and balance sheet, but today’s price assumes multiple years of execution with little operating or rate disappointment.
The collector’s GAAP EPS and revenue fields are not the correct REIT decision metrics and are not used as the primary variance. The relevant dated hurdle was normalized FFO around the mid-$1.50s; $1.60 cleared it. FY1 rises to the $6.36–$6.44 company range. FY2 should be built from occupancy runway, RevPOR, labor cost, development yields, and share count after the call. Business delta: positive. Estimate delta: positive. Stock delta: neutral-to-negative because the premium multiple remains.
At a $6.40 FFO midpoint, 34x implies $218, 38x implies $243, and 42x implies $269. The close sits above the central case and below a scarcity-premium bull case. New money therefore needs either a price reset toward $220 or evidence that FY27 FFO can compound at a rate that lowers the effective multiple quickly. The raised dividend is supportive, but the dividend yield is not the valuation anchor for a high-growth healthcare REIT.
Old narrative: a senior-housing recovery with rare balance-sheet capacity. New narrative: the recovery has matured into high-teens same-store NOI and a raised dividend, but the equity already prices a long runway. Action: HOLD; wait below about $220. Confirmation: SHO NOI at least 18.5%, occupancy gains above 200 basis points, leverage near 3x, and accretive deployment. Falsification: SHO NOI below 12%, RevPOR below labor inflation, leverage above 4x, or dilution without FFO accretion.
The call is scheduled for 2026-07-28. Current Q&A, prior-quarter language delta, labor/agency-cost detail, and external-growth underwriting are exact pending inputs.
Source: Welltower Q2 release.
Decision: HOLD/WAIT; prefer entry below roughly $220. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Q2 GAAP EPS was $5.04 and adjusted EPS was $4.84 after excluding a $0.20 Helion benefit. Sales were $10.40B and EBITDA $2.02B. Steel-mill pre-tax earnings rose to $1.556B from $1.128B in Q1 and $843M a year ago; steel products improved to $353M from $276M sequentially, while raw materials reached $146M from $45M. The result confirms strong cycle momentum, but $130M of raw-material cash refunds benefited cost of goods sold and should not be annualized.
Management expects Q3 earnings to increase again on higher steel prices with stable mill volumes and better steel-products price/volume, partly offset by lower raw-material margins. Cash of $2.69B supports the capital plan. The central question is how much of the current earnings step is a durable policy/supply-cycle benefit versus transitory price and refund support.
Nucor’s structural edge is its variable-cost electric-arc-furnace footprint, raw-material optionality, and downstream steel-products exposure. Those advantages create better downside resilience than an integrated mill, but they do not eliminate cycle risk. Higher domestic prices can attract imports, weaken end-user demand, and invite destocking. The $130M refund and $0.20 Helion item are separately identified because capitalizing them would overstate the normalized run rate.
The adjusted EPS base and Q3 direction make the FY1 estimate delta positive. FY2 remains exposed to domestic utilization, imports, construction demand, and the timing/returns of growth projects. At $247.86, the market already discounts a favorable cycle. Business delta: positive. Estimate delta: positive. Stock delta: neutral. Old narrative: a high-quality steel operator waiting for price/utilization recovery. New narrative: the recovery is present and broadening, but one-time COGS support and a cyclical multiple discipline matter.
The decision range is deliberately below the close. A bear value in the high $180s assumes pricing normalizes and projects dilute near-term returns; a base around $225–$235 assumes current mill profitability fades gradually; a bull above $270 requires sustained trade protection, high utilization, and downstream strength. The current price assigns meaningful probability to the bull. The call must supply realized price, shipment, import, backlog, and project-return evidence before that probability can be raised. Until then, cyclically elevated earnings receive no terminal multiple.
Action: HOLD; wait below about $220 for new money. Confirmation: Q3 adjusted EPS above Q2, stable shipments, higher realized pricing, and project returns above cost of capital. Falsification: mill utilization reversal, imports eroding price, products backlog weakening, or capex rising into a downcycle. The call is scheduled for 2026-07-28; shipment/price bridge, refund treatment, project-capex returns, and complete Q&A are still explicitly pending.
Source: Nucor Q2 release public mirror.
Decision: HOLD; prefer entry below roughly $365. Confidence: medium. Status: PROVISIONAL — RELEASE ONLY. Revenue rose 11% to $865M. Systems revenue grew 32% to $240M, software 7% to $223M, and services 3% to $402M. Gross margin was 82.2%, non-GAAP operating margin 35.0%, and non-GAAP EPS $4.73 versus $4.16 a year ago. Management raised FY26 revenue growth to 9%–10% from 7%–8% and non-GAAP EPS to $17.21–$17.33 from $16.25–$16.55. Q4 guidance is $870M–$890M revenue and $4.14–$4.26 EPS.
The operating upside is hardware-led, which improves current growth but can be less recurring than software. The critical call issue is whether Systems growth reflects a durable refresh cycle, AI/data-center security demand, or supply/timing. Services remain the stabilizer, and the 82% gross margin shows the portfolio still has strong economics. At $407.96, the stock trades around 23.7x the new FY26 EPS midpoint, a reasonable but not cheap price for high-single/low-double-digit growth.
The product mix needs careful interpretation. Systems demand can create strong revenue and operating leverage when customers refresh appliances, but it can also pull demand forward. Software growth is more strategically valuable because it supports recurring economics and hybrid/multicloud relevance; its 7% rate is healthy but not yet a reacceleration. Services at 3% provide resilience, though a mature maintenance base cannot carry the premium alone. The release supports a balanced model, not a pure AI-security growth label.
Business delta: positive. Estimate delta: positive. Stock delta: neutral after a 4.02% gain. Old narrative: a mature application-delivery vendor transitioning toward software and security. New narrative: a systems refresh is accelerating the whole portfolio while software/services protect margin, but durability must be proven. Action: HOLD; prefer entry below $365. Confirmation: Q4 revenue above $870M, software growth at least mid-single digits, and non-GAAP margin near 35%. Falsification: systems contraction without software acceleration, services weakness, or FY guide reversal.
At the new $17.27 EPS midpoint, 21x implies about $363, 24x about $414, and 27x about $466. The close is already around the central multiple. Upside requires a credible path to double-digit software/product growth after the systems refresh; downside appears if product normalizes while services stay low single digits. The missing call must distinguish order timing from installed-base expansion and reconcile backlog, channel inventory, recurring software mix, renewal duration, and customer-budget sensitivity. Those inputs determine whether the raised guide is a durable reset or a refresh-cycle peak.
The call occurred, but the complete transcript and prior-quarter Q&A comparison were not publicly indexed by cutoff. Product-duration, backlog, AI-security contribution, channel inventory, renewal cadence, and management tone currently remain exact pending inputs.
Source: F5 Q3 FY26 issuer release.
The following rows are valid deferrals, not omissions. Each company was in the deterministic Nasdaq-derived PM universe above $2B, but the available evidence did not clear the complete primary-release/transcript/expectations gate needed for a decision-grade section by 20:00 EDT. Catch-up deadline is 2026-07-28 08:00 EDT unless noted.
| Ticker | Market cap | Close / day | Known fact at cutoff | Missing decision datum | Required question |
|---|---|---|---|---|---|
| CINF | $28.28B | day +0.78% | Scheduled AMC; insurer | Current primary release, combined-ratio reserve bridge, full Q&A | Was underwriting margin driven by current accident-year improvement or reserve releases? |
| PFG | $23.63B | day +1.73% | Scheduled AMC; retirement/insurance | Primary release, spread/flows consensus, full Q&A | Are retirement flows and spread income accelerating after credit normalization? |
| BRO | $22.93B | day +3.02% | Scheduled AMC; broker | Primary organic-growth/margin release and transcript | How much growth is price versus exposure/unit expansion? |
| SUI | $15.01B | day -0.32% | Scheduled AMC; residential REIT | Core FFO, same-property NOI, MH/RV occupancy, call | Do core operations offset capital and balance-sheet pressure? |
| UDR | $12.86B | day -0.81% | Scheduled AMC; apartment REIT | FFO, blended lease spreads, concessions, call | Is coastal rent growth reaccelerating without higher concessions? |
| TFII | $12.38B | day -3.03% | Scheduled AMC; transport | Primary segment margin and tonnage release, transcript | Has LTL utilization turned before pricing weakens? |
| SANM | $11.17B | day +0.23% | Scheduled AMC; electronics manufacturing | Primary release, communications/cloud mix, call | Is AI/networking demand converting to margin and cash? |
| RMBS | $10.38B | day +0.43% | Scheduled AMC; semiconductor IP | Royalty/product revenue bridge and full Q&A | Are DDR5/HBM royalties accelerating faster than product cyclicality? |
| TIMB | $10.19B | day -1.97% | Scheduled AMC; telecom | Brazil ARPU/churn, capex and FCF release, call | Does price-led growth convert to FCF after spectrum and capex? |
| BRX | $9.95B | day -0.28% | Scheduled AMC; shopping-center REIT | FFO, leasing spreads, occupancy, transcript | Are leasing spreads sustaining NOI after financing costs? |
| UHS | $9.43B | day +2.29% | Scheduled AMC; hospitals/behavioral | Segment admissions, pricing, labor and full Q&A | Is acute/behavioral labor leverage durable and volume-led? |
| ESI | $9.12B | day +1.07% | Scheduled AMC; specialty chemicals | Electronics segment volume/margin and call | Does semiconductor demand offset industrial cyclicality? |
| SSD | $7.98B | day -0.33% | Scheduled AMC; building products | Volume/price, housing channel inventory, call | Is repair/remodel stabilizing before pricing normalizes? |
| APLD | $7.77B | $26.38 / -3.00% | Scheduled AMC; data-center developer | Primary project milestones, funding, tenant economics, call | Are energization and financing milestones de-risked without dilutive capital? |
| NE | $6.90B | day -0.35% | Scheduled AMC; offshore drilling | Backlog/day-rate/fleet-status release and call | Are leading-edge day rates holding as new supply returns? |
| KRC | $4.58B | day -0.03% | Scheduled AMC; office REIT | Leasing, occupancy, FFO and liquidity call | Do West Coast leasing gains offset rollover and financing pressure? |
| CDP | $4.31B | day +0.63% | Scheduled AMC; REIT | Primary property/FFO release and full Q&A | What is the organic NOI and leverage path after portfolio changes? |
| AGYS | $2.78B | day +4.77% | Scheduled AMC; hospitality software | Subscription ARR, payments, margin, transcript | Is recurring growth accelerating without implementation bottlenecks? |
| NBTB | $2.72B | day +0.27% | Scheduled AMC; bank | NIM/deposit-cost/credit release and call | Is funding beta stabilizing before asset repricing slows? |
| HTO | $2.67B | day -0.53% | Scheduled AMC | Primary issuer release and business-specific KPIs | Which reported driver clears the dated consensus and valuation hurdle? |
| NVTS | $2.62B | day +4.49% | Scheduled AMC; power semiconductors | Revenue design-win conversion, cash burn, call | When do GaN/SiC design wins become volume and gross margin? |
| NTB | $2.44B | day -0.46% | Scheduled AMC; bank | NIM, non-interest deposits, credit, transcript | Does offshore funding protect margin without new credit cost? |
| NWBI | $2.25B | day +0.06% | Scheduled AMC; bank | Primary release, NIM/deposit/credit bridge, call | Is the balance-sheet remix accretive after funding cost? |
| BLX | $2.22B | day -0.34% | Collector had no verified actual | Primary release, NIM/fees/credit and transcript | Is trade-finance growth producing risk-adjusted spread expansion? |
| HAPN | $2.08B | day +3.82% | Collector had no verified actual | Primary release, listing/issuer KPI validation, call | What evidence supports the move and clears the earnings hurdle? |
WHR exclusion: Whirlpool’s issuer communication rescheduled the earnings release to 2026-08-03 and the call to 2026-08-04. It is not a failed 2026-07-27 reporter and is excluded rather than deferred.
/Users/max/morningsignal-research/collect_earnings_context.py --date 2026-07-27 --session PM/Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-27_PM.jsongenerate_earnings_brief, or run_daily.py was used.